Jupiter Neurosciences, Inc. (JUNS)

NCM – Real Time Price. Currency in USD

0.28

+0.04 (18.34%)

At close: Jun 26, 2026, 4:00 PM EDT

0.21

-0.07 (-25.18%)

After-hours: Jun 26, 2026, 7:59 PM EDT

27.05.2026

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available

26.05.2026

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").

21.05.2026

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering").

20.05.2026

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.

20.05.2026

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares are trading higher Wednesday after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.

20.05.2026

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine

04.05.2026

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Jupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announced today that it will be participating in the Market Movers Investor Summit on Tuesday May 5, 2026. The presentation will take place at 09:00 AM ET at the historic Bank of New York.

Videos

No Data

There is no data to display

Press releases

27.05.2026

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available

26.05.2026

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

21.05.2026

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

20.05.2026

Jupiter Neurosciences, Inc. (JUNS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jupiter Neurosciences, Inc. (JUNS)

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Search stocks

Jupiter Neurosciences, Inc. (JUNS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jupiter Neurosciences, Inc. (JUNS)

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering